LEGN Legend Biotech Corp
- Stocks
- Healthcare
- NASDAQ: LEGN
Price (delayed)
$32.01
Market cap
$5.91B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$5.33B
Relative Growth:
Rel. Growth:
58
Relative Strength:
Rel. Strength:
21
Relative Valuation:
Rel. Valuation:
10
Relative Profitability:
Rel. Profitability:
26
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated
Highlights
The gross profit has soared by 81% YoY and by 4.4% from the previous quarter
The revenue has surged by 75% year-on-year and by 9% since the previous quarter
The gross margin has contracted by 4.6% from the previous quarter but it has grown by 3.6% YoY
The company's net income fell by 49% QoQ and by 14% YoY
The EPS has declined by 48% since the previous quarter and by 16% year-on-year
Key stats
What are the main financial stats of LEGN
Market
Valuations
Earnings
Shares outstanding
184.57M
Market cap
$5.91B
Enterprise value
$5.33B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.69
Price to sales (P/S)
7.39
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.69
Revenue
$796.84M
Gross profit
$498.11M
Operating income
-$142.07M
Net income
-$325.33M
EBIT
-$283.36M
EBITDA
-$260.04M
Free cash flow
-$317.31M
Per share
Balance sheet
Liquidity
EPS
-$1.78
EPS diluted
-$1.78
Free cash flow per share
-$1.72
Book value per share
$5.63
Revenue per share
$4.33
TBVPS
$9.17
Total assets
$1.69B
Total liabilities
$654.38M
Debt
$387.91M
Equity
$1.04B
Working capital
$984.39M
Debt to equity
0.37
Current ratio
4.71
Quick ratio
3.75
Net debt/EBITDA
2.23
Margins
Efficiency
Dividend
EBITDA margin
-32.6%
Gross margin
62.5%
Net margin
-40.8%
Operating margin
-17.8%
Return on assets
-19.4%
Return on equity
-30.9%
Return on invested capital
-40.6%
Return on capital employed
-19.9%
Return on sales
-35.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEGN stock price
How has the Legend Biotech stock price performed over time
Intraday
-0.12%
1 week
-0.37%
1 month
-0.16%
1 year
-28.26%
YTD
-1.63%
QTD
-1.84%
Financial performance
How have Legend Biotech's revenue and profit performed over time
Revenue
$796.84M
Gross profit
$498.11M
Operating income
-$142.07M
Net income
-$325.33M
Gross margin
62.5%
Net margin
-40.8%
The gross profit has soared by 81% YoY and by 4.4% from the previous quarter
The operating margin has soared by 75% YoY and by 20% QoQ
The revenue has surged by 75% year-on-year and by 9% since the previous quarter
LEGN's operating income has soared by 56% year-on-year and by 12% since the previous quarter
Price vs fundamentals
How does LEGN's price correlate with its fundamentals
Growth
What is Legend Biotech's growth rate over time
Valuation
What is Legend Biotech stock price valuation
P/E
N/A
P/B
5.69
P/S
7.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.69
The EPS has declined by 48% since the previous quarter and by 16% year-on-year
The stock's price to book (P/B) is 50% less than its 5-year quarterly average of 11.4 and 12% less than its last 4 quarters average of 6.5
The equity is down by 11% YoY
The P/S is 86% less than the 5-year quarterly average of 51.0 and 32% less than the last 4 quarters average of 10.8
The revenue has surged by 75% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Legend Biotech business performance
The company's return on equity has shrunk by 54% QoQ and by 33% YoY
LEGN's return on assets has dropped by 52% since the previous quarter and by 24% year-on-year
The return on sales has declined by 47% since the previous quarter but it has increased by 39% year-on-year
LEGN's return on invested capital is down by 47% since the previous quarter and by 3% year-on-year
Dividends
What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEGN.
Financial health
How did Legend Biotech financials performed over time
Legend Biotech's total assets is 158% more than its total liabilities
The quick ratio has contracted by 16% YoY and by 13% from the previous quarter
The total liabilities has increased by 9% QoQ and by 2.4% YoY
Legend Biotech's debt is 63% lower than its equity
The debt to equity has grown by 28% YoY and by 2.8% from the previous quarter
Legend Biotech's debt has increased by 14% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.